182 related articles for article (PubMed ID: 7872323)
21. The influence of gender, weight, height and BMI on pentosidine concentrations in plasma of hemodialyzed patients.
Slowick-Zylka D; Safranow K; Dziedziejko V; Dutkiewicz G; Ciechanowski K; Chlubek D
J Nephrol; 2006; 19(1):65-9. PubMed ID: 16523428
[TBL] [Abstract][Full Text] [Related]
22. Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids.
Ueda Y; Miyata T; Goffin E; Yoshino A; Inagi R; Ishibashi Y; Izuhara Y; Saito A; Kurokawa K; Van Ypersele De Strihou C
Kidney Int; 2000 Dec; 58(6):2518-24. PubMed ID: 11115086
[TBL] [Abstract][Full Text] [Related]
23. Quantification of the cross-link pentosidine in serum from normal and uremic subjects.
Takahashi M; Kushida K; Kawana K; Ishihara C; Denda M; Inoue T; Horiuchi K
Clin Chem; 1993 Oct; 39(10):2162-5. PubMed ID: 8403403
[TBL] [Abstract][Full Text] [Related]
24. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy.
Suliman ME; Heimbürger O; Bárány P; Anderstam B; Pecoits-Filho R; Rodríguez Ayala E; Qureshi AR; Fehrman-Ekholm I; Lindholm B; Stenvinkel P
J Am Soc Nephrol; 2003 Jun; 14(6):1614-22. PubMed ID: 12761263
[TBL] [Abstract][Full Text] [Related]
25. Daily haemodialysis improves indices of protein glycation.
Floridi A; Antolini F; Galli F; Fagugli RM; Floridi E; Buoncristiani U
Nephrol Dial Transplant; 2002 May; 17(5):871-8. PubMed ID: 11981076
[TBL] [Abstract][Full Text] [Related]
26. Plasma advanced glycosylation end-products in maintenance haemodialysis patients.
Odetti P; Cosso L; Pronzato MA; Dapino D; Gurreri G
Nephrol Dial Transplant; 1995 Nov; 10(11):2110-3. PubMed ID: 8643178
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of glyoxal and methylglyoxal levels in uremic patients under peritoneal dialysis.
Lapolla A; Flamini R; Lupo A; Aricò NC; Rugiu C; Reitano R; Tubaro M; Ragazzi E; Seraglia R; Traldi P
Ann N Y Acad Sci; 2005 Jun; 1043():217-24. PubMed ID: 16037242
[TBL] [Abstract][Full Text] [Related]
28. A sensitive and specific ELISA for plasma pentosidine.
Izuhara Y; Miyata T; Ueda Y; Suzuki D; Asahi K; Inagi R; Sakai H; Kurokawa K
Nephrol Dial Transplant; 1999 Mar; 14(3):576-80. PubMed ID: 10193802
[TBL] [Abstract][Full Text] [Related]
29. Association between pentosidine and arteriosclerosis in patients receiving hemodialysis.
Kitauchi T; Yoshida K; Yoneda T; Saka T; Yoshikawa M; Ozono S; Hirao Y
Clin Exp Nephrol; 2004 Mar; 8(1):48-53. PubMed ID: 15067516
[TBL] [Abstract][Full Text] [Related]
30. Nonenzymatic cross-linking pentosidine increase in bone collagen and are associated with disorders of bone mineralization in dialysis patients.
Mitome J; Yamamoto H; Saito M; Yokoyama K; Marumo K; Hosoya T
Calcif Tissue Int; 2011 Jun; 88(6):521-9. PubMed ID: 21499867
[TBL] [Abstract][Full Text] [Related]
31. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds.
Henle T; Deppisch R; Beck W; Hergesell O; Hänsch GM; Ritz E
Nephrol Dial Transplant; 1999 Aug; 14(8):1968-75. PubMed ID: 10462279
[TBL] [Abstract][Full Text] [Related]
32. Impact of residual renal function on plasma levels of advanced oxidation protein products and pentosidine in peritoneal dialysis patients.
Furuya R; Kumagai H; Odamaki M; Takahashi M; Miyaki A; Hishida A
Nephron Clin Pract; 2009; 112(4):c255-61. PubMed ID: 19546585
[TBL] [Abstract][Full Text] [Related]
33. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine.
Miyata T; Ueda Y; Shinzato T; Iida Y; Tanaka S; Kurokawa K; van Ypersele de Strihou C; Maeda K
J Am Soc Nephrol; 1996 Aug; 7(8):1198-206. PubMed ID: 8866413
[TBL] [Abstract][Full Text] [Related]
34. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia.
Miyata T; Ueda Y; Yamada Y; Izuhara Y; Wada T; Jadoul M; Saito A; Kurokawa K; van Ypersele de Strihou C
J Am Soc Nephrol; 1998 Dec; 9(12):2349-56. PubMed ID: 9848790
[TBL] [Abstract][Full Text] [Related]
35. Association of serum pentosidine with arterial stiffness in hemodialysis patients.
Zhou Y; Yu Z; Jia H; Sun F; Ma L; Guo R; Peng L; Cui T
Artif Organs; 2010 Mar; 34(3):193-9. PubMed ID: 20447043
[TBL] [Abstract][Full Text] [Related]
36. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product.
Sugiyama S; Miyata T; Ueda Y; Tanaka H; Maeda K; Kawashima S; Van Ypersele de Strihou C; Kurokawa K
J Am Soc Nephrol; 1998 Sep; 9(9):1681-8. PubMed ID: 9727377
[TBL] [Abstract][Full Text] [Related]
37. Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients.
Furuya R; Kumagai H; Takahashi M; Sano K; Hishida A
Blood Purif; 2005; 23(4):311-6. PubMed ID: 15980621
[TBL] [Abstract][Full Text] [Related]
38. Correlation between pentosidine and endothelin-1 in subjects undergoing chronic hemodialysis.
Odetti P; Monacelli F; Storace D; Robaudo C; Rossi S; Deferrari G; Barreca T
Horm Metab Res; 2006 Dec; 38(12):817-20. PubMed ID: 17163357
[TBL] [Abstract][Full Text] [Related]
39. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers.
Miyata T; Ishiguro N; Yasuda Y; Ito T; Nangaku M; Iwata H; Kurokawa K
Biochem Biophys Res Commun; 1998 Mar; 244(1):45-9. PubMed ID: 9514872
[TBL] [Abstract][Full Text] [Related]
40. Pyridoxamine improves functional, structural, and biochemical alterations of peritoneal membranes in uremic peritoneal dialysis rats.
Kakuta T; Tanaka R; Satoh Y; Izuhara Y; Inagi R; Nangaku M; Saito A; Miyata T
Kidney Int; 2005 Sep; 68(3):1326-36. PubMed ID: 16105068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
